PMID- 26219967
OWN - NLM
STAT- MEDLINE
DCOM- 20170707
LR  - 20220409
IS  - 2184-8777 (Electronic)
IS  - 0303-464X (Linking)
VI  - 40
IP  - 2
DP  - 2015 Apr-Jun
TI  - Clinical significance of matrix metalloproteinase-3 in systemic lupus 
      erythematosus patients: a potential biomarker for disease activity and damage.
PG  - 145-9
AB  - OBJECTIVES: To assess the serum level of matrix metalloproteinase-3 (MMP-3) in 
      systemic lupus erythematosus (SLE) patients and correlate it with clinical 
      manifestations, laboratory findings, disease activity and damage. METHODS: 
      Forty-two female SLE patients were included in the present study. Full history 
      taking, thorough examination and investigations were performed. Disease activity 
      was assessed using the SLE disease activity index (SLEDAI). Furthermore, Systemic 
      Lupus International Collaborating Clinics /American College of Rheumatology 
      damage index (SLICC/ACR DI) was also assessed. Renal biopsy was done in those 
      with lupus nephritis. Thirty age and sex matched subjects were included as 
      control. Serum MMP-3 was measured by ELISA. RESULTS: The mean serum MMP-3 level 
      in SLE patients was significantly higher (80.9+/-45.8 ng/ml) than in the control 
      (10.01+/-2.6 ng/ml) (p <0.0001). The level in patients with arthritis, nephritis or 
      hematologic disorders were significantly higher than in those without (p<0.0001, 
      p=0.02 and p=0.04 respectively). The MMP-3 was significantly different among the 
      subclasses of renal biopsy (p=0.01) being higher in those with class IV 
      (137.5+/-45.6 ng/ml). It significantly correlated with the SLEDAI, SLICC, white 
      blood cells and platelet counts (r=0.37, p=0.02; r=0.36, p=0.02; r=0.32, p 0.04 
      and r=0.38, p=0.01 respectively). On linear regression analysis with age, disease 
      duration and body mass index as independent factors, the SLEDAI and SLICC were 
      not significant predictors. CONCLUSION: Serum MMP-3 was found to be high in SLE 
      patients and associated with arthritis, nephritis and hematological 
      manifestations. Matrix metalloproteinase-3 correlated with disease activity and 
      damage making it a possible biomarker and its measure of considerable interest 
      related to the potential therapeutic responses and disease outcome.
FAU - Gheita, T A
AU  - Gheita TA
FAU - Abdel Rehim, D M
AU  - Abdel Rehim DM
FAU - Kenawy, S A
AU  - Kenawy SA
FAU - Gheita, H A
AU  - Gheita HA
LA  - eng
PT  - Journal Article
PL  - Portugal
TA  - Acta Reumatol Port
JT  - Acta reumatologica portuguesa
JID - 0431702
RN  - 0 (Biomarkers)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - Female
MH  - Humans
MH  - Lupus Erythematosus, Systemic/*blood/*diagnosis
MH  - Matrix Metalloproteinase 3/*blood
MH  - Severity of Illness Index
EDAT- 2015/07/30 06:00
MHDA- 2017/07/08 06:00
CRDT- 2015/07/30 06:00
PHST- 2015/07/30 06:00 [entrez]
PHST- 2015/07/30 06:00 [pubmed]
PHST- 2017/07/08 06:00 [medline]
PST - ppublish
SO  - Acta Reumatol Port. 2015 Apr-Jun;40(2):145-9.